SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff, which traders link to the Democrats midterm gains and fears that political pushback could slow AI and data-center expansion, has put SPY in focus as tech and semiconductor shares unwind. The community is divided between calling the decline an overreaction and buying the dip versus expecting further downside amid volatility and selling pressure.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

NLST is under pressure amid a broad selloff in technology and memory stocks, with traders debating whether concerns about AI/data-center investment and policy risks or company-specific factors are driving the decline. Many are treating the pullback as a buying opportunity ahead of the Q3 report, while watching for an SK Hynix agreement and developments in Netlists Kingston litigation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigels quarterly results and early VEPPANU launch are driving discussion: traders are encouraged by the drugs initial uptake and record product sales, but some focus on the earnings miss, weaker margins, and cash burn. The stocks sharp decline has sharpened the debate over whether VEPPANUs growth potential outweighs the disappointing headline results.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is under pressure as traders question whether Big Techs heavy AI and data-center spending will generate returns quickly enough to offset its effect on free cash flow. The community is split between fears of a deeper tech correction and views that the selloff is a rotation or pullback creating a buying opportunity.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XE is drawing attention amid a sharp selloff, with traders citing broader weakness in nuclear stocks and concerns about post-IPO share supply and bearish analyst coverage. Some are buying the dip on the strength of Amazon-backed reactor projects and federal support, while others worry that commercialization and meaningful revenue remain years away.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings disappointing Q3 results and lowered full-year outlook triggered a sharp selloff, with traders criticizing rising costs and managements heavy investment in its Predictions business. The main debate is whether that investment can build a growth engine or instead leaves DraftKings vulnerable to competition from Kalshi and Polymarket and delays profitability.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzles Q3 results beat expectations and management raised its FY2026 outlook while issuing a positive initial FY2027 forecast, fueling a sharp rally. Bulls point to continued growth and profitability, while some traders warn that valuation and a slower projected growth pace could weigh on the stock; short-squeeze talk is speculative.

Teradyne, Inc.. The Group's principal activity is to design, manufacture, sell and service automatic test equipment for electronic companies. It operates in two segments: Semiconductor Test Systems and System Test Group. Semiconductor Test Systems segment designs, manufactures, sells and supports Semiconductor Test products and services on a world wide basis. Systems Test Group segment is comprised of 3 business units: Mil/Aero, Commercial Board Test and Diagnostic Solutions. It also operates in the Semiconductor Test; Military/Aerospace test, Commercial Circuit Board test and Automotive Diagnostics test. On 14-Nov-2008, it acquired Eagle Test Systems Inc, On 24-Jan-2008, it acquired Nextest Systems Corporation ('Nextest').

Teradyne, Inc.

Teradynes sharp selloff despite a strong quarterly beat is driving discussion, with traders pointing to cautious near-term guidance, margin pressure and valuation concerns. Some see the drop as a buying opportunity, while others question whether AI-related chip-testing demand can sustain the stocks prior gains.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is under pressure amid a broad crypto and tech selloff, with traders linking its decline to weakness in Bitcoin and Ethereum. Many complain that the stock is falling harder than ETH and criticize Tom Lees stewardship, while others see the discount to asset value and share buybacks as reasons to buy the dip.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is caught in a sharp semiconductor selloff as traders worry that post-midterm calls for tighter data-center rules could slow AI infrastructure spending and chip demand. The community is split between seeing the drop as an overreaction and buying opportunity, and expecting more downside if AI-capex growth or data-center expansion slows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases PR Newswire HAMBURG, Germany, Aug. 6, 2026 Collaboration combines Odyssey's disease...

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Equity

The Boston-based clinical-stage biopharmaceutical company raised $279 million through an upsized offering, issuing 15.5 million shares of its common stock.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. Its programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.

Odyssey Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Odyssey Therapeutics stated that it had also raised an additional $25 million through a private placement of 1.39 million shares of its common stock to an affiliate of TPG Life Sciences Innovations.</li><li>Odyssey plans to use the proceeds of the offering and private placement to advance the development of OD-001, its most advanced drug candidate for the treatment of ulcerative colitis and Crohn’s disease.</li><li>It also disclosed plans to advance its SLC15A4 program and to fund additional discovery, preclinical, and clinical activities for disclosed or future programs.</li></ul>Shares of Odyssey Therapeutics Inc. (ODTX) gained nearly 13% in its debut on the Nasdaq on Friday, reaching a valuation of $900 million as equity markets hover near new all-time highs.<a href="https://stocktwits.com/symbol/ODTX">Odyssey Therapeutics shares</a> debuted on the Nasdaq at $20. However, the stock has lost all its gains at the time of writing, trading nearly 10% lower at $16 per share, compared to its issue price of $18 per share.The Boston-based clinical-stage biopharmaceutical company raised $279 million through an upsized offering, issuing 15.5 million shares of its common stock. The company also stated that the underwriters have an option to purchase up to an additional 2.33 million shares within 30 days from the date of issue.Retail sentiment on Stocktwits around Odyssey Therapeutics trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">ODTX Raises Additional $25M From Private Placement</h2>Odyssey Therapeutics stated that it had also raised an additional $25 million through a private placement of 1.39 million shares of its common stock to an affiliate of TPG Life Sciences Innovations at the IPO price of $18 per share.Overall, Odyssey’s gross proceeds from the public issue and the private placement stood at $304 million.The company had previously filed for an IPO in 2025, but withdrew it a few months later.Odyssey plans to use the proceeds of the offering and private placement to advance the development of OD-001, its most advanced drug candidate for the treatment of ulcerative colitis and Crohn’s disease. It also disclosed plans to advance its SLC15A4 program and to fund additional discovery, preclinical, and clinical activities for disclosed or future programs.<h2 class="st-heading-2">What Does ODTX Do?</h2>Odyssey Therapeutics is a clinical-stage biotech company developing targeted treatments for autoimmune and inflammatory diseases.Founded in 2021, the company has built an internally developed pipeline of drug candidates that precisely target disease pathways and deliver deeper, longer-lasting remission for patients with unmet medical needs.According to the company’s filings with the U.S. Securities and Exchange Commission (SEC), Odyssey reported a net loss of $148.6 million in 2025, while its net loss for 2024 stood at $129.3 million.Odyssey stated that it had $175.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026.The Renaissance IPO ETF (IPO) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/groupon-missed-q1-estimates-why-is-grpn-stock-soaring-today/cZX28P9Reg7">GRPN Stock Heads For Best Day In A Year Despite Earnings Miss — Here’s Why CEO Senkypl Is Confident About ‘Stronger Performance Ahead’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an IPO (Initial public offering) words are seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Renaissance Capital Greenwich Funds - Renaissance IPO ETF

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Current Price	$18.88
Prev Close	$19.50
Open	$19.50
Dividend Yield	N/A
50-Day Moving Average	$21.31
Beta	0.45
Avg. Volume	244,468.69
PE Ratio	-5.94

52-Week High	$29.05
52-Week Low	$15.10
Market Capitalization	$937.14M
EPS (Annual)	-$3.15
Price to Book	2.41
Revenue Per Employee	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

ODTX Fundamentals